Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech

Bruker Corporation (Nasdaq: BRKR) is pleased to announce the closing of its acquisition of ELITechGroup (“ELITech”) for €870 million in cash, excluding the carved out ELITech clinical chemistry business. ELITech is a differentiated, fast growing and profitable provider of systems and assays for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology, with FY 2023 revenue of approximately EUR 150 million, and more than 80% consumables revenue.

Read the full article: Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech //

Source: https://www.businesswire.com/news/home/20240502163748/en/Bruker-Completes-Acquisition-of-Molecular-Diagnostics-Innovator-ELITech

Leave a Comment

Your email address will not be published.

Scroll to Top